Axsome Therapeutics AXSM incurred an adjusted loss of 97 cents per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.00. The company had incurred a loss ...

Q2 2025 Earnings Call Transcript August 4, 2025 Axsome Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.92 ...

Axsome Therapeutics Inc (AXSM) reports a 72% year-over-year revenue increase, driven by strong product sales and strategic ...

Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY® ...

Double-digit prescription gains for its commercial drugs, major coverage wins, and the early launch of a new migraine therapy were the most significant highlights. Despite substantial progress, the ...

Discover Axsome Therapeutics' Q2 2025 earnings highlights, including 72% revenue growth, new product launch SYMBRAVO, and promising neuroscience ...

Axsome Therapeutics reported quarterly losses of 47 cents per share compared to analyst consensus estimate of losses of $1.07 per share. The company reported quarterly sales of $150.04 million which ...

Axsome Therapeutics reported record total product revenues of $150 million for the quarter, marking a 72% increase year-over-year and a 24% increase quarter-over-quarter. This impressive growth ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) saw its shares climb more than 5% in pre-market trading Monday, following the release of its second-quarter results that topped Wall Street estimates thanks to ...